News Daily News Evinacumab Helps Severe Hypercholesterolemia Patients Reach LDL Targets Michael O'Riordan September 14, 2023
News Daily News Acute MI Patients Without Standard CVD Risk Factors at Higher Risk of Death Michael O'Riordan July 07, 2023
News Daily News Oxidized Phospholipids and Lp(a) Strongly Associated With MACE: CASABLANCA Michael O'Riordan May 03, 2023
News Daily News How Lp(a) Levels Compare With LDL-C in FH: Some Surprises Michael O'Riordan November 17, 2022
News Conference News AHA 2022 ‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE Michael O'Riordan November 06, 2022
News Features Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD? Michael O'Riordan August 15, 2022
News Daily News Lp(a) Levels Linked to Aortic Valve Calcification, Not Progression Michael O'Riordan August 08, 2022
News Conference News ACC 2022 Modest Effects, Safety Concerns Plague Vupanorsen in TRANSLATE-TIMI 70 Michael O'Riordan April 07, 2022
News Conference News EAS 2020 Lp(a) and LPA Genetic Risk Score Both Predict Incident ASCVD: UK Biobank Michael O'Riordan October 07, 2020
News Daily News High Levels of Lp(a) Linked to Increased Ischemic Stroke Risk Michael O'Riordan July 01, 2019
News Conference News EAS 2019 Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role Michael O'Riordan June 07, 2019
News Daily News Will Less Aggressive Lp(a) Targets Do the Trick? Time and Clinical Trials Will Tell Yael L. Maxwell April 24, 2019
News Conference News AHA 2018 Novel Inhibitor of Apolipoprotein(a) Production Lowers Lp(a) in Phase II Study Shelley Wood November 11, 2018
News Daily News Therapies Aimed at New Genetic Target Show Early Promise for Lowering Triglycerides Todd Neale May 26, 2017
News Conference News AHA 2016 PCSK9 Inhibition and Other New Therapies for Lipid Modification: Good News and Bad Michael O'Riordan November 15, 2016